References
- Mancuso ME, Biasoli C, Marino R, et al. Physical activity, bleedings and quality of life in subjects with haemophilia A without inhibitors – A multicenter, observational italian study with a wearable device. J Clin Med 2024; 13(11): 3036. doi: 10.3390/jcm13113036.
- Ransmann P, Brühl M, Hmida J, et al. Physical activity and handgrip strength in patients with mild, moderate and severe haemophilia: Impacts on bone quality and lean mass. PLoS One 2025; 20(3): e0319951. doi: 10.1371/journal.pone.0319951.
- Goto M, Takedani H, Yokota K, Haga N. Strategies to encourage physical activity in patients with hemophilia to improve quality of life. J Blood Med 2016; 7: 85–98. doi: 10.2147/JBM.S84848.
- Negrier C, Seuser A, Forsyth A, et al. The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity. Haemophilia 2013; 19(4): 487–98. doi: 10.1111/hae.12118.
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046.
- Kahan S, Cuker A, Kushner RF, et al. Prevalence and impact of obesity in people with haemophilia: Review of literature and expert discussion around implementing weight management guidelines. Haemophilia 2017; 23(6): 812–20. doi: 10.1111/hae.13291.
- Biasoli C, Baldacci E, Coppola A, et al. Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project. Blood Transfus 2022; 20(1): 66–77. doi: 10.2450/2021.0138-21.
- Kennedy M, O'Gorman P, Monaghan A, et al. A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. Haemophilia 2021; 27(4): 544–62. doi: 10.1111/hae.14282.
- Cotino C, Pérez-Alenda S, Cruz-Montecinos C, et al. Barriers and facilitators of physical activity in adults with severe haemophilia: A qualitative study. Haemophilia 2023; 29(5): 1334–42. doi: 10.1111/hae.14828.
- Cecchini C, Creighton K, Hann A, et al. Destination fitness 2nd edition [Internet]. Canadian Hemophilia Society; 2012. Available from
https://www.hemophilia.ca/files/Destination%20 fitness%20-%20FINAL.pdf (accessed March 2025). - Zourikian N, Jarock C, Mulder K. All About Hemophilia: A Guide for Families Chapter 12-Physical Activity, Exercise and Sports, 2nd edition [Internet]. Canadian Hemophilia Society; 2012. Available from
https://www.hemophilia.ca/files/Chapter%2012.pdf (accessed April 2025). - Anderson A, Forsyth A. Playing it safe: Bleeding disorders, sports, and exercise [Internet]. National Hemophilia Foundation; 2005. Available from
https://www.hemophilia.ca/files/PlayingItSafe.pdf (accessed March 2025). - Anderson A, Forsyth A. Playing it safe: Bleeding disorders, sports, and exercise [Internet]. National Hemophilia Foundation; 2017. Available from
https://www.bleeding.org/sites/default/files/document/files/playing-it-safe_0.pdf (accessed April 2025). - Fong E, Brooks J, Jones C, et al. In the Driver's seat [Internet]. Canadian Hemophilia Society; 2012. Available from
https://www.hemophilia.ca/edmat-physical-activity-and-sports/ (accessed April 2025). - Mancuso ME, Croteau SE, Klamroth R. Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies. Haemophilia 2024; 30 Suppl 3: 39–44. doi: 10.1111/hae.14976.
- McLaughlin P, Hurley M, Chowdary P, Stephensen D, Khair K. The experiences and beliefs of people with severe haemophilia and healthcare professionals on pain management, and their views of using exercise as an aspect of intervention: a qualitative study. Disabil Rehabil 2022; 44(26): 8420–8. doi: 10.1080/09638288.2021.2018054.
- McLaughlin P, Hurley M, Chowdary P, Stephensen D, Khair K. How does a lifetime of painful experiences influence sensations and beliefs about pain in adults with severe haemophilia? A qualitative study. Disabil Rehabil 2022; 44(26): 8412–9. doi: 10.1080/09638288.2021.2018053.
- Matlary RED, Grinda N, Sayers F, Versloot O, McLaughlin P. Promoting physical activity for people with haemophilia in the age of new treatments. Haemophilia 2022; 28(6): 885–90. doi: 10.1111/hae.14641.
- Stephensen D, Rodriguez-Merchan EC. Orthopaedic comorbidities in the elderly haemophilia population: a review. Haemophilia 2013; 19(2): 166–73. doi: 10.1111/hae.12006.
- Taylor S, Toye F, Donovan-Hall M, Barker K. Past the tipping point: a qualitative study of the views and experiences of men with haemophilia regarding mobility, balance, and falls. Disabil Rehabil 2022; 44(23): 7237–45. doi: 10.1080/09638288.2021.1988731.
- Bukkems LH, Versloot O, Cnossen MH, et al. Association between sports participation, Factor VIII levels and bleeding in Hemophilia A. Thromb Haemost 2023; 123(3): 317–25. doi: 10.1055/a-1983-0594.
- Versloot O, Kemler E, Blokzijl J, et al. Clotting factor activity levels and bleeding risk in people with haemophilia playing sports. Haemophilia 2023; 29(4): 1013–23. doi: 10.1111/hae.14800.
- Martin AP, Burke T, Asghar S, et al. Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise. Haemophilia 2020; 26(4): 711–7. doi: 10.1111/hae.13985.
- Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: The ups and downs of treatment. Blood Rev 2021; 50: 100852. doi: 10.1016/j.blre.2021.100852.
- Tomschi F, Hmida J, Herzig S, et al. Physical activity and factor VIII levels in patients with haemophilia: A real-world prospective observational study. Haemophilia 2024; 30(2): 419–25. doi: 10.1111/hae.14965.
- Mulvany R, Zucker-Levin AR, Jeng M, et al. Effects of a 6-week, individualized, supervised exercise program for people with bleeding disorders and hemophilic arthritis. Phys Ther 2010; 90(4): 509–26. doi: 10.2522/ptj.20080202.
- Pinto PR, Paredes AC, Moreira P, et al. Emotional distress in haemophilia: Factors associated with the presence of anxiety and depression symptoms among adults. Haemophilia 2018; 24(5): e344–e53. doi: 10.1111/hae.13548.
- Witkop ML, Lambing A, Nichols CD, et al. Interrelationship between depression, anxiety, pain, and treatment adherence in hemophilia: results from a US cross-sectional survey. Patient Prefer Adherence 2019; 13: 1577–87. doi: 10.2147/PPA.S212723.
- Eather N, Wade L, Pankowiak A, Eime R. The impact of sports participation on mental health and social outcomes in adults: a systematic review and the 'Mental Health through Sport' conceptual model. Syst Rev 2023; 12(1): 102. doi: 10.1186/s13643-023-02264-8.
- Rodríguez MA, Pérez-Alenda S, Carrasco JJ, et al. Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia. Thromb Res 2024; 244: 109181. doi: 10.1016/j.thromres.2024.109181.
- WHO Guidelines on Physical Activity and Sedentary Behaviour [Internet]. Geneva: World Health Organization; 2020. Available from
https://iris.who.int/bitstream/handle/10665/336656/9789240015128-eng.pdf?sequence=1 (accessed April 2025). - Gogia P, Tarantino M, Schramm W, Aledort L. New directions to develop therapies for people with hemophilia. Expert Rev Hematol 2023;16(6): 417–33. doi: 10.1080/17474086.2023.2184341.
- Dargaud Y, Volot F, Desage S, et al. Haemophilia prophylaxis in the age of innovation: exploring opportunities for personalized treatment. Haemophilia 2025; 31(4): 607–16. doi: 10.1111/hae.70015.
- Blokzijl J, Timmer MA, van Vulpen LFD. Movement behavior in hemophilia-from medicalized training approaches toward an active lifestyle. Res Pract Thromb Haemost 2021; 5(8): e12639. doi: 10.1002/rth2.12639.
- McLaughlin P, Holland M, Dodgson S, Khair K. Project GYM: A randomized feasibility study investigating effect on motivation of personal trainer-led exercise in young men with hemophilia. Res Pract Thromb Haemost 2021; 5(8): e12613. doi: 10.1002/rth2.12613.
- Kwasnicka D, Dombrowski SU, White M, Sniehotta F. Theoretical explanations for maintenance of behaviour change: a systematic review of behaviour theories. Health Psychol Rev 2016; 10(3): 277–96. doi: 10.1080/17437199.2016.1151372.
- Varma N, Han JK, Passman R, et al. Promises and perils of consumer mobile technologies in cardiovascular care: JACC Scientific Statement. J Am Coll Cardiol 2024; 83(5): 611–31. doi: 10.1016/j.jacc.2023.11.024.
- Dodd C, Hashem F, Stephensen D, Bassett P. Wearable activity trackers in young people with haemophilia: What needs to be considered? Haemophilia 2023; 29(3): 942–5. doi: 10.1111/hae.14790.
- Ginsburg GS, Picard RW, Friend SH. Key issues as wearable digital health technologies enter clinical care. N Engl J Med 2024; 390(12): 1118–27. doi: 10.1056/NEJMra2307160.
- Swan H, Shin SW. Wearable digital health technologies in clinical care. N Engl J Med 2024; 390(22): 2131. doi: 10.1056/NEJMc2404921.
- Zapotocka E, Batorova A, Bilic E, et al. florio® HAEMO: A longitudinal survey of patient preference, adherence and wearable functionality in Central Europe. Adv Ther 2024; 41(7): 2791–807. doi: 10.1007/s12325-024-02872-3.
- Matlary RED, Grydeland M, Glosli H, Rueegg CS, Holme PA. Physical activity in Norwegian teenagers and young adults with haemophilia A compared to general population peers. Haemophilia 2023; 29(2): 658–67. doi: 10.1111/hae.14752.
- Pérez-Alenda S, Carrasco JJ, Querol-Fuentes F, et al. Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up. Haemophilia 2024; 30(3): 791–9. doi: 10.1111/hae.14988.
- Iorio A, Iserman E, Blanchette V, et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia 2017; 23(3): e170–e9. doi: 10.1111/hae.13215.
- den Uijl IE, Fischer K, Van Der Bom JG, et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17(1): 41–4. doi: 10.1111/j.1365-2516.2010.02383.x.
- Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308(14): 1452–9. doi: 10.1001/jama.2012.12727.
- Sun SX, Crawford S. Microsimulation to compare activity-related bleed risks between pharmacokinetic-guided rurioctocog alfa pegol prophylaxis and emicizumab. Expert Rev Hematol 2023; 16(3): 205–11. doi: 10.1080/17474086.2023.2162498.
- Ai D, Huang K, Li G, et al. Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A. Front Pediatr 2022; 10: 1045070. doi: 10.3389/fped.2022.1045070.
- Konkle BA, Quon DV, Raffini L, et al. A prospective observational study of antihemophilic factor (recombinant) prophylaxis related to physical activity levels in patients with hemophilia A in the United States (SPACE). J Blood Med 2021; 12: 883–96. doi: 10.2147/JBM.S327180.
- Srichumpuang C, Rakmanotham A, Moonla C, Sosothikul D. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis. Orphanet J Rare Dis 2024; 19(1): 135. doi: 10.1186/s13023-024-03092-2.
- von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388(4): 310–8. doi: 10.1056/NEJMoa2209226.
- DiBenedetti D, Neme D, Pan-Petesch B, et al. Patient experience with efanesoctocog alfa for severe hemophilia A: Results from the XTEND-1 phase 3 clinical study exit interviews. Clin Ther 2024; 46(12): 1016–23. doi: 10.1016/j.clinthera.2024.09.010.
- Lim MY. How do we optimally utilize factor concentrates in persons with hemophilia? Hematology Am Soc Hematol Educ Program 2021; 2021(1): 206–14. doi: 10.1182/hematology.2021000310.
- Lewandowska M, Nasr S, Shapiro AD. Emerging therapies in hemophilia: Improving equitable access to care. J Blood Med 2025; 16: 95–115. doi: 10.2147/JBM.S490588.
- Scott LJ, Kim ES. Emicizumab-kxwh: First global approval. Drugs 2018; 78(2): 269–74. doi: 10.1007/s40265-018-0861-2.
- Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia 2022; 28(S4): 103–10. doi: 10.1111/hae.14524.
- Astermark J, Ranta S, Myrin Westesson L, et al. Health-related quality of life (HRQoL), physical activity (PA) and joint health in people with severe haemophilia A (PwSHA) and a bleeding phenotype receiving emicizumab – results from the HemiNorth 2 study (PO081). 18th Annual Congress of the European Association for Haemophilia and Allied Disorders. February 4–7, 2025. Milan, Italy.
- Amano K, Fujii T, Sawada A, et al. TSUBASA study: evaluating association of physical activity and bleeding events in people with haemophilia A without factor VIII inhibitors receiving emicizumab. Haemophilia 2025; 31(4): 703–12. doi: 10.1111/hae.70070.
- Hermans C, Negrier C, Lehle M, et al. Emicizumab prophylaxis for the treatment of people with moderate or mild hemophilia A without Factor VIII inhibitors: Results from the primary analysis of the HAVEN 6 Study. International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting; July 9–13, 2022; London, England.
- Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9) :811–22. doi: 10.1056/NEJMoa1803550.
- Nogami K, Fujii T, Sawada A, et al. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study. Int J Hematol 2024;119(1): 14–23. doi: 10.1007/s12185-023-03679-8.
- Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–18. doi: 10.1056/NEJMoa1703068.
- Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6(6): e295–e305. doi: 10.1016/S2352-3026(19)30054-7.
- Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 2019; 25(6): 979–87. doi: 10.1111/hae.13848.
- Skinner MW, Négrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27(5): 854–65. doi: 10.1111/hae.14363.
- Warren BB, Chan A, Manco-Johnson M, et al. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report. Res Pract Thromb Haemost 2021; 5(5): e12571. doi: 10.1002/rth2.12571.
- Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134(24): 2127–38. doi: 10.1182/blood.2019001869.
- Itzler R, Buckner TW, Leebeek FWG, et al. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy. Haemophilia 2024; 30(3): 709–19. doi: 10.1111/hae.14977.
- Angchaisuksiri P, von Mackensen S, Apte S, et al. Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study. Res Pract Thromb Haemost 2025; 9(2): 102705. doi: 10.1016/j.rpth.2025.102705.
- Ozelo MC, Mason J, Dunn AL, et al. Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study. J Thromb Haemost 2025; 23(5): 1496–506. doi: 10.1016/j.jtha.2024.12.038.
- Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med 2023; 388(8): 694–705. doi: 10.1056/NEJMoa2211075.
- Leavitt AD, Mahlangu J, Raheja P, et al. Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial. Res Pract Thromb Haemost 2024; 8(8): 102615. doi: 10.1016/j.rpth.2024.102615.
- Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022; 386(11): 1013–25. doi: 10.1056/NEJMoa2113708.
- Matsushita T, Shapiro A, Abraham A, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med 2023; 389(9): 783–94. doi: 10.1056/NEJMoa2216455.
- Kavakli K, Cuker A, Frenzel L, et al. Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: Results from the BENEGENE-2 trial. J Thromb Haemost 2025; S1538-7836(25)00648-8. doi: 10.1016/j.jtha.2025.09.029. Online ahead of print.
- Madan B, Ozelo MC, Raheja P, et al. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost 2024; 22(7): 1880–93. doi: 10.1016/j.jtha.2024.04.001.
- Matino D, Palladino A, Taylor CT, et al. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood 2025;146(14): 1654–63. doi: 10.1182/blood.2024027468.
- O'Mahony B, Dunn AL, Leavitt AD, et al. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost 2023; 21(12): 3450–62. doi: 10.1016/j.jtha.2023.08.032.
- Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med 2023; 388(8): 706–18. doi: 10.1056/NEJMoa2211644.
- Pipe SW, Lissitchkov T, Georgiev P, et al. Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B. Blood Adv 2025; 9(5): 1147–58. doi: 10.1182/bloodadvances.2024013900.
- Tran H, von Mackensen S, Abraham A, et al. Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study. Res Pract Thromb Haemost 2024; 8(4): 102476. doi: 10.1016/j.rpth.2024.102476.
- Von Mackensen S CP, Mangles S, Yu Q, Mei B, Andersson SR, Dasmahapatra P. Fitusiran treatment impacts on health-related quality of life in subjects with hemophilia A and B with inhibitors assessed with the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL). Blood 2020; 136(Supplement 1): 23–4. doi: 10.1182/blood-2020-142266.
- Kenet G, Nolan B, Zulfikar B, et al. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood 2024; 143(22): 2256–69. doi: 10.1182/blood.2023021864.
- Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol 2023; 10(5): e322–e32. doi: 10.1016/S2352-3026(23)00037-6.
- Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet 2023; 401(10386): 1427–37. doi: 10.1016/S0140-6736(23)00284-2.
- Franchini M, Marano G, Pati I, et al. Emicizumab for the treatment of haemophilia A: a narrative review. Blood Transfus 2019; 17(3): 223–8. doi: 10.2450/2019.0026-19.
- Batsuli G, Wheeler AP, Weyand AC, Sidonio RF, Jr., Young G. Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort. Am J Hematol 2023; 98(10): E285–e7. doi: 10.1002/ajh.27039.
- Villarreal Martinez L CK, Laursen J, Odgaard-Jensen J, You CW, Windyga J. Active lifestyle in patients with hemophilia A or B with inhibitors on once-daily subcutaneous concizumab prophylaxis: Results from the phase 3 explorer7 study. Blood 2022; 140(Supplement 1): 5634–6. doi: 10.1182/blood-2022-167076.
- Jiménez-Yuste V, Chan A, Obeid J, et al. Active lifestyle in patients with haemophilia A or B with and without inhibitors on once-daily subcutaneous concizumab prophylaxis: Results from the phase 3 explorer7 and explorer8 trials (MP-018). Presented at the 2024 International World Congress of the World Federation of Hemophilia. April 21–24, 2024; Madrid, Spain.
- von Mackensen S, Bagot CN, Lienhart A, et al. Health-related quality of life in adults with haemophilia B after gene therapy with fidanacogene elaparvovec in the BENEGENE-2 trial (PO116). Presented at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders. February 6–9, 2024; Messe Frankfurt, Spain.
- Karimi M, Bourke S, Little M, et al. Health-related quality of life improvements following valoctocogene roxaparvovec gene therapy in people without bleeds or target joints at baseline: A post hoc analysis from GENER8-1 (PP-160). Presented at the 2024 International World Congress of the World Federation of Hemophilia. April 21–24, 2024; Madrid, Spain.
- Pipe S, Abdelkader W, Clearfield E, et al. Gene therapy with the Padua variant of a codon-optimised human factor IX gene etranacogene dezaparvovec in people with haemophilia B: Effects on patient-oriented outcomes measured using the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire in the HOPE-B study (PP-164). Presented at the 2024 International World Congress of the World Federation of Hemophilia. April 21–24, 2024; Madrid, Spain.
- Afonso M, Srivastava A, Rangarajan S, et al. Improved overall quality of life and treatment satisfaction in patients with haemophilia receiving fitusiran: Analyses of qualitative semi-structured interviews of participants in the ATLAS-OLE trial (PO089). 18th Annual Congress of the European Association for Haemophilia and Allied Disorders. February 4–7, 2025. Milan, Italy.
- Pfizer Halts Production of FDA-Approved Hemophilia B Gene Therapy [Internet]. Association for the Advancement of Blood and Biotherapies; 2025. Available from
https://www.aabb.org/news-resources/news/article/2025/02/25/pfizer-halts-production-of-fda-approved-hemophilia-b-gene-therapy (accessed November 2025). - von Mackensen S, Ducore JM, George LA, et al. Health-related quality of life in adults with hemophilia B after receiving gene therapy with fidanacogene elaparvovec. Blood 2023; 142(Supplement 1): 3628. doi: 10.1182/blood-2023-179431.
- Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125(13): 2038–44. doi: 10.1182/blood-2015-01-528414.
- Peyvandi F, Seidizadeh O, Mohsenian S, Garagiola I. Exploring nonreplacement therapies' impact on hemophilia and other rare bleeding disorders. Res Pract Thromb Haemost 2024; 8(4): 102434. doi: 10.1016/j.rpth.2024.102434.
- Chen Y, Cheng SJ, Thornhill T, Solari P, Sullivan SD. Health care costs and resource use of managing hemophilia A: A targeted literature review. J Manag Care Spec Pharm 2023; 29(6): 647–58. doi: 10.18553/jmcp.2023.29.6.647.
- Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13 Suppl 2: 16–22. doi: 10.1111/j.1365-2516.2007.01501.x.
- Perolla A, Kalaja B. Improving hemophilia care in low- and middle-income countries: addressing challenges and enhancing quality of life. Cureus 2024; 16(6): e62817. doi: 10.7759/cureus.62817.
- John MJ, Stonebraker J, Jindal A, et al. Global prophylaxis trends in hemophilia: a macroeconomic analysis and its association with world development indicators. Expert Rev Hematol 2024; 17(12): 947–56. doi: 10.1080/17474086.2024.2429606.
- World Federation of Hemophilia Humanitarian Aid Program: Impact Report 2024 [Internet]. World Federation of Hemophilia; 2024. Available from
https://wfh.org/wp-content/uploads/2025/04/wfh-humanitarian-aid-impact-report-2024.pdf (accessed November 2025). - Pierce GF, Adediran M, Diop S, et al. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol 2022; 9(9): e689–e97. doi: 10.1016/S2352-3026(22)00209-5.
- de Kleijn P, Duport G, Jansone K, et al. European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients. Haemophilia 2022; 28(4): 649–55. doi: 10.1111/hae.14566.
- Zhou ZY, Riske B, Forsberg AD, et al. Self-reported barriers to hemophilia care in people with factor VIII deficiency. Am J Prev Med 2011; 41(6 Suppl 4): S346–53. doi: 10.1016/j.amepre.2011.09.003.
- Timmer MA, Blokzijl J, Schutgens REG, Veenhof C, Pisters MF. Coordinating physiotherapy care for persons with haemophilia. Haemophilia 2021; 27(6): 1051–61. doi: 10.1111/hae.14404.
- Skinner MW, Nugent D, Wilton P, et al. Achieving the unimaginable: Health equity in haemophilia. Haemophilia 2020; 26(1): 17–24. doi: 10.1111/hae.13862.